Table 2 Characteristics of the cohorts with tests (n = 430)
Covariate | Level | GA (Non-Epidural) N = 215 | Epidural N = 215 | P-value |
|---|---|---|---|---|
Gender | Male | 176 (81.86) | 156 (72.56) | 0.021 |
Female | 39 (18.14) | 58 (27.44) | ||
Age (years) | Median | 70 | 69 | 0.384 |
Follow-up (months) | Median | 40.7 | 42.9 | 0.260 |
Race | Unknown/Other | 7 (3.26) | 2 (0.93) | 0.181 |
White | 197 (91.63) | 207 (96.28) | ||
Black | 8 (3.72) | 6 (2.79) | ||
Asian | 1 (0.47) | 0 (0) | ||
Hawaiian/P. Islander | 1 (0.47) | 0 (0) | ||
Indian/Alaskan | 1 (0.47) | 0 (0) | ||
Ethnicity | Unknown/Other | 138 (64.19) | 140 (66.12) | 0.977 |
Not Hispanic/Latino | 73 (33.95) | 71 (33.02) | ||
Hispanic/Latino | 4 (1.86) | 4 (1.86) | ||
ASA | 1 | 1 (0.47) | 2 (0.93) | 0.147 |
2 | 86 (40) | 108 (50.23) | ||
3 | 123 (57.21) | 101 (46.98) | ||
4 | 5 (2.33) | 4 (1.86) | ||
Length of stay (days) | Median | 8 | 7 | 0.352 |
BMI (kg/m2) | Median | 28.46 | 27.75 | 0.191 |
pT stage | T0 | 31 (14.42) | 28 (13.02) | 0.096 |
T1 | 20 (9.3) | 24 (11.16) | ||
T2 | 30 (13.95) | 52 (24.19) | ||
T3 | 71 (33.02) | 54 (25.12) | ||
T4 | 31 (14.42) | 31 (14.42) | ||
Ta/Tis | 32 (14.88) | 26 (12.09) | ||
pN stage | Nx | 10 (4.65) | 9 (4.19) | 0.808 |
N1 | 19 (8.84) | 16 (7.44) | ||
N2 | 33 (15.35) | 27 (12.56) | ||
N3 | 7 (3.26) | 10 (4.65) | ||
N0 | 146 (67.91) | 153 (71.16) | ||
Neoadjuvant chemotherapy | No | 155 (72.77) | 150 (70.09) | 0.540 |
Yes | 58 (27.23) | 64 (29.91) |